Compare Raytheon Technologies Corp (RTX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs TG Therapeutics Inc — how do they compare? Raytheon Technologies Corp trades at $184.82 (market cap $248.42B), while TG Therapeutics Inc trades at $54.85 (market cap $8.16B). The key difference: Raytheon Technologies Corp is far larger — about 30.4× TG Therapeutics Inc's market cap, and Raytheon Technologies Corp pays a 1.58% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raytheon Technologies Corp for 78 Days and TG Therapeutics Inc for 15 Days on average.
| RTX | TGTX | |
|---|---|---|
Market Cap | $248.42B | $8.16B |
Volume | 4,380,368 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $225.49 | $59.06 |
52-Week Low | $157.00 | $26.94 |
Typical Hold Time | 78 Days | 15 Days |
Enterprise Value | $278.97B | $8.37B |
Dividend Yield | 1.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $180.26, down 1.65% today, amid a bearish technical signal but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q3 2026 EPS expected at $1.77. Revenue grew to $88.6B in 2025, with net income margin improving to 7.59%. Analyst consensus remains strongly bullish with a $236.27 price target and 65% buy ratings, supported by a $289B backlog and defense sector tailwinds.
The outlook for RTX is positive given robust defense spending, earnings momentum, and analyst confidence. Risks include execution on large contracts, debt levels, and geopolitical uncertainties. The stock offers growth potential with a 30% upside to consensus target, but investors should monitor quarterly execution and defense budget developments.
TG Therapeutics (TGTX) trades at $52.95, up 1.46% on the day, with a bearish technical signal from moving averages despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results have missed expectations. Analyst sentiment remains largely positive, with an 84.62% buy rating and a consensus price target of $80.50, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook for TGTX is mixed, with robust revenue guidance and product momentum offset by earnings misses and negative cash flow. Key opportunities include BRIUMVI's expanding market share and potential buyout speculation, but risks involve ongoing legal scrutiny, competitive pressures, and the need to translate top-line growth into consistent bottom-line performance amid significant cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
